| In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic Frontiers in chemistry 7, 873, 2020 | 87 | 2020 |
| Modulating protein–protein interactions with visible‐light‐responsive peptide backbone photoswitches L Albert, A Peñalver, N Djokovic, L Werel, M Hoffarth, D Ruzic, J Xu, ... ChemBioChem 20 (11), 1417-1429, 2019 | 40 | 2019 |
| Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention D Ruzic, N Djoković, T Srdić-Rajić, C Echeverria, K Nikolic, JF Santibanez Pharmaceutics 14 (1), 209, 2022 | 29 | 2022 |
| The oxidoreductase PYROXD1 uses NAD (P)+ as an antioxidant to sustain tRNA ligase activity in pre-tRNA splicing and unfolded protein response I Asanović, E Strandback, A Kroupova, D Pasajlic, A Meinhart, ... Molecular Cell 81 (12), 2520-2532. e16, 2021 | 22 | 2021 |
| Bistable photoswitch allows in vivo control of hematopoiesis L Albert, J Nagpal, W Steinchen, L Zhang, L Werel, N Djokovic, D Ruzic, ... ACS central science 8 (1), 57-66, 2021 | 18 | 2021 |
| Structure-based design of selective histone deacetylase 6 zinc binding groups LA Alves Avelar, D Ruzic, N Djokovic, T Kurz, K Nikolic Journal of Biomolecular Structure and Dynamics 38 (11), 3166-3177, 2020 | 11 | 2020 |
| Fragment-based drug design of selective HDAC6 inhibitors D Ruzic, N Djokovic, K Nikolic Protein-Ligand Interactions and Drug Design, 155-170, 2021 | 10 | 2021 |
| Discovery of 1-benzhydryl-piperazine-based HDAC inhibitors with anti-breast cancer activity: synthesis, molecular modeling, in vitro and in vivo biological evaluation D Ruzic, B Ellinger, N Djokovic, JF Santibanez, S Gul, M Beljkas, A Djuric, ... Pharmaceutics 14 (12), 2600, 2022 | 9 | 2022 |
| Synthesis, in silico, and in vitro studies of novel dopamine D2 and D3 receptor ligands M Elek, N Djokovic, A Frank, S Oljacic, A Zivkovic, K Nikolic, H Stark Archiv der Pharmazie 354 (6), 2000486, 2021 | 9 | 2021 |
| An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ... Molecular Informatics 40 (5), 2000187, 2021 | 8 | 2021 |
| Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics N Djokovic, D Ruzic, M Rahnasto-Rilla, T Srdic-Rajic, ... Journal of Chemical Information and Modeling 62 (10), 2571-2585, 2022 | 6 | 2022 |
| Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein C Bon, Y Si, M Pernak, M Barbachowska, E Levi-Acobas, V Cadet Daniel, ... Molecules 26 (17), 5300, 2021 | 5 | 2021 |
| Reversible control of RNA splicing by photoswitchable small molecules L Zhang, X Xie, N Djokovic, K Nikolic, D Kosenkov, F Abendroth, ... Journal of the American Chemical Society 145 (23), 12783-12792, 2023 | 4 | 2023 |
| Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma N Djokovic, A Djuric, D Ruzic, T Srdic-Rajic, K Nikolic Pharmaceuticals 16 (2), 294, 2023 | 3 | 2023 |
| Medicinal chemistry of histone deacetylase inhibitors D Ružić, N Djoković, K Nikolić, Z Vujić Archives of Pharmacy 71 (Notebook 2), 73-100, 2021 | 2 | 2021 |
| SIRT2i_Predictor: A machine learning-based tool to facilitate the discovery of novel SIRT2 inhibitors N Djokovic, M Rahnasto-Rilla, N Lougiakis, M Lahtela-Kakkonen, ... Pharmaceuticals 16 (1), 127, 2023 | 1 | 2023 |
| Discovery of 1-benzhydryl piperazine-based HDAC inhibitors with anti-cancer and anti-metastatic properties against human breast cancer: synthesis, molecular modeling, in vitro … D Ruzic, M Petkovic, N Djokovic, J Santibanez, B Ellinger, M Beljkas, ... | 1 | 2022 |
| Discovery of 1-benzhydryl-piperazine-based HDAC inhibitors with anti-breast cancer activity: synthesis, molecular modeling, in vitro and in vivo biological evaluation D Ružić, B Ellinger, N Đoković, JF Santibanez, S Gul, M Beljkaš, A Đurić, ... Pharmaceutics 14 (12), 2600, 2022 | 1 | 2022 |
| Rational design of selective histone deacetylase inhibitors D Ružić, N Đoković, M Petković, D Agbaba, M Lahtela-Kakkonen, ... Physical Chemistry 2018 (Proceedings) 14th International Conference on …, 2018 | 1 | 2018 |
| Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer M Beljkas, A Ilic, A Cebzan, B Radovic, N Djokovic, D Ruzic, K Nikolic, ... Pharmaceutics 15 (11), 2581, 2023 | | 2023 |
